Floatz logo

Rapamycin

Adult Acute Monoblastic Leukemia (M5a)

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Adult Acute Monoblastic Leukemia (M5a) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Chinese PLA General Hospital
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB
Cyclophosphamide
ECOG-ACRIN Cancer Research Group
Phase 3BBB

View all 50 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →